GHK-Cu: Copper Peptide Research in Skin, Wound Healing, and Tissue Repair

There are basically two GHK-Cu stories, and people keep telling them as one. Rubbed on skin, it has a reasonable body of evidence going back to the 1970s. Injected, which is what the performance and longevity crowd actually wants, the evidence is thin. The compound’s long research history gets borrowed to vouch for a use it was barely tested for. Keep those two apart and the picture gets honest fast.

What GHK-Cu is

GHK-Cu (glycyl-L-histidyl-L-lysine:copper 2+) is a natural three-amino-acid peptide that binds copper ions. It shows up in human plasma, saliva, and urine, and plasma levels drop as you age, which is what got aging researchers interested. The copper-binding part isn’t decoration: the bare GHK tripeptide behaves differently from the copper-complexed form.

It was first isolated and characterised in Loren Pickart’s lab in the 1970s at the University of California San Francisco. Early work pegged it as a plasma factor that influenced liver-cell division, tying it to tissue-growth regulation. Decades of follow-on research widened the studied applications to wound healing, anti-inflammatory effects, collagen and elastin production, and gene-expression changes.

What the evidence actually shows

GHK-Cu’s evidence base is broader than most compounds here: preclinical, in vitro, and some clinical.

In animals, GHK-Cu speeds wound contraction and healing across several experimental systems. Applied topically, it raised wound healing rates in rodent incision and excision models, with tissue evidence of more collagen and less inflammatory cell infiltration. A 2018 review in the International Journal of Molecular Sciences by Pickart and Margolina pulled together the regenerative and protective evidence alongside new gene-expression data. Rodents. Topical.

In vitro, GHK-Cu drives fibroblast growth, turns up collagen and elastin gene expression, and shifts a strikingly broad set of gene programmes. A genomic study from the 2010s claimed it changed the expression of over 4,000 genes. That sounds impressive. It also raises a specificity problem: a compound touching that many genes at once may be working through non-specific mechanisms, and the literature hasn’t resolved it.

Human clinical data is thinner. GHK-Cu has been tested in topical wound-dressing use in small clinical studies, generally positive on wound closure. Topical cosmetic formulations have a bigger pile of consumer-facing skincare data, generally lower quality than pharmaceutical studies.

The injectable use, the context the longevity community cares about most, has a much thinner evidence base than the topical literature. That’s the asymmetry to remember.

Two regulatory worlds, two answers

GHK-Cu’s status is layered, because it lives in two regulatory worlds: skincare (cosmetic rules) and injectable compounded preparations (pharmaceutical rules).

As a topical skincare ingredient, it’s broadly available in cosmetic formulations without a prescription. Cosmetic use doesn’t carry drug claims and sits under different FDA oversight than pharmaceutical use.

As an injectable compounded preparation, the picture is more layered than it first looks. GHK-Cu isn’t on the PCAC July 23–24, 2026 review docket — Federal Register notice 2026-07361, which lists the substances nominated for that meeting, doesn’t include it.

But the same April 2026 FDA action that scheduled the July meeting also scheduled a second PCAC meeting before the end of February 2027, and GHK-Cu is on it — alongside Melanotan II, LL-37, Dihexa acetate, and PEG-MGF.

The route split is the editorial detail. The two halves moved in opposite directions on the 503A bulk substances lists. Injectable GHK-Cu came off Category 2 — the FDA’s do not compound / significant-safety-concerns list — so the form people would actually inject is no longer formally banned from compounding. Non-injectable GHK-Cu went the other way: it was pulled out of Category 1, the under evaluation list that had temporarily allowed compounding under enforcement discretion, so topical GHK-Cu actually lost a safe harbor it used to have.

Both forms are slated for the February 2027 PCAC consultation. The injectable form — the form anyone compounding GHK-Cu for systemic use would actually prepare — is the reason Category 2 moved, and the reason GHK-Cu is on the second-wave docket at all.

What nobody has answered yet

The human evidence for injectable GHK-Cu is thin next to the topical literature. Injection is a different beast pharmacokinetically and pharmacodynamically from rubbing it on skin, and it lacks the controlled trial data that would make it a validated medical intervention.

The 4,000-gene claim is a mechanism question, not a selling point. A compound moving that many gene programmes at once may be acting non-specifically, or its effects may be heavily context-dependent. The clinical meaning of that breadth isn’t understood.

Long-term safety of injected GHK-Cu in humans hasn’t been characterised in published clinical studies. Its copper-binding behaviour raises questions about local and systemic copper metabolism at injectable doses that nobody has studied in people.

The honest picture

GHK-Cu has a longer, broader research history than most peptides in this series, anchored by genuine preclinical evidence for wound healing and skin biology. The topical evidence is reasonably substantial. The injectable evidence is thin. The gap between marketing claims for injectable GHK-Cu and the clinical evidence backing them is wide.

The honest framing: the topical space stays active and relatively unencumbered; the injectable space’s compounding question is scheduled for the second-wave PCAC meeting before February 2027, with the injectable route as the editorially load-bearing form on that docket; the strength of the topical literature shouldn’t be used to vouch for the injectable use ahead of that consultation.